INmune Bio Valuation
| INMB Stock | USD 1.58 0.01 0.63% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. INmune Bio retains a regular Real Value of $1.43 per share. The prevalent price of the firm is $1.58. Our model calculates the value of INmune Bio from evaluating the firm fundamentals such as Return On Asset of -0.51, shares outstanding of 26.59 M, and Return On Equity of -1.56 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting INmune Bio's valuation include:
Price Book 1.6342 | Enterprise Value | Enterprise Value Ebitda (5.31) | Price Sales 845.4113 | Enterprise Value Revenue 296.38 |
Overvalued
Today
Please note that INmune Bio's price fluctuation is dangerous at this time. Calculation of the real value of INmune Bio is based on 3 months time horizon. Increasing INmune Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since INmune Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of INmune Stock. However, INmune Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.58 | Real 1.43 | Target 5.25 | Hype 1.58 | Naive 1.55 |
The real value of INmune Stock, also known as its intrinsic value, is the underlying worth of INmune Bio Company, which is reflected in its stock price. It is based on INmune Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of INmune Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of INmune Bio helps investors to forecast how INmune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of INmune Bio more accurately as focusing exclusively on INmune Bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use INmune Bio's intrinsic value based on its ongoing forecasts of INmune Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against INmune Bio's closest peers. If more than one evaluation category is relevant for INmune Bio we suggest using both methods to arrive at a better estimate.
INmune Bio Cash |
|
INmune Bio Total Value Analysis
INmune Bio is currently expected to have valuation of 14.82 M with market capitalization of 42.27 M, debt of 384 K, and cash on hands of 61.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the INmune Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.82 M | 42.27 M | 384 K | 61.21 M |
INmune Bio Investor Information
About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. INmune Bio recorded a loss per share of 2.11. The entity had not issued any dividends in recent years. Based on the analysis of INmune Bio's profitability, liquidity, and operating efficiency, INmune Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.INmune Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. INmune Bio has an asset utilization ratio of 0.0354 percent. This suggests that the Company is making $3.54E-4 for each dollar of assets. An increasing asset utilization means that INmune Bio is more efficient with each dollar of assets it utilizes for everyday operations.INmune Bio Profitability Analysis
Considering INmune Bio's profitability and operating efficiency indicators, INmune Bio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess INmune Bio's ability to earn profits and add value for shareholders.Net Loss | First Reported 2016-09-30 | Previous Quarter -24.5 M | Current Value -6.5 M | Quarterly Volatility 4.8 M |
For INmune Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of INmune Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well INmune Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between INmune Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of INmune Bio over time as well as its relative position and ranking within its peers.
INmune Bio Earnings per Share Projection vs Actual
By analyzing INmune Bio's earnings estimates, investors can diagnose different trends across INmune Bio's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for INmune Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.INmune Bio Ownership Allocation
INmune Bio has a total of 26.59 Million outstanding shares. INmune Bio retains 17.01 (percent) of its outstanding shares held by insiders and 17.47 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.INmune Bio Profitability Analysis
The company reported the previous year's revenue of 14 K. Net Loss for the year was (42.08 M) with profit before overhead, payroll, taxes, and interest of 50 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates INmune Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in INmune Bio and how it compares across the competition.
About INmune Bio Valuation
The stock valuation mechanism determines INmune Bio's current worth on a weekly basis. Our valuation model uses a comparative analysis of INmune Bio. We calculate exposure to INmune Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of INmune Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 12.6 K | 12 K | |
| Pretax Profit Margin | -3.5 K | -3.3 K | |
| Operating Profit Margin | -3.5 K | -3.3 K | |
| Net Loss | -3.5 K | -3.3 K |
INmune Bio Current Valuation Indicators
Valuation refers to the process of determining the present value of INmune Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value INmune we look at many different elements of the entity such as INmune's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as INmune Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use INmune Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes INmune Bio's worth.Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |